I'm a title. ​Click here to edit me.

Overview

ApoRx is a drug discovery company focusing on the discovery, design, characterization, and development of small proteolysis targeting molecules (PTMs) against well-validated disease-causing proteins in cancer and other indications.

The core of our technology is the 'Aperion library' - a proprietary focus library of RING E3 ligase binders that is designed to harness the intracellular Ubiquitin-Proteasome machinery to degrade and destroy unwanted proteins by Targeted Protein Degradation.